Covid 19 Research using Clinical Trials (Home Page)
Recombinant novel coronavirus vaccine (Adenovirus type 5 vector)Wiki
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (2)
Correlated MeSH Terms (1)
|
Name (Synonyms) |
Correlation |
D000257 | Adenoviridae Infections NIH | 0.71 |
Correlated HPO Terms (0)
|
Name (Synonyms) |
Correlation |
There is one clinical trial.
Clinical Trials
This is a phase II, randomised, double-blinded and placebo-controlled clinical trial in
healthy adults above 18 years of age. This clinical trial is designed to evaluate the
immunogenicity and safety of Ad5-nCoV which encodes for a full-length spike (S) protein of
SARS-CoV-2.
NCT04341389 COVID-19 Biological: Recombinant novel coronavirus vaccine (Adenovirus type 5 vector) Other: Placebo
Primary Outcomes
Measure: Occurrence of adverse reactions Time: 0-14 days post vaccination
Measure: Anti SARS-CoV-2 S IgG antibody response(ELISA) Time: 28 days post vaccination
Measure: Neutralizing antibody response to SARS-CoV-2 Time: 28 days post vaccination
Secondary Outcomes
Measure: Occurrence of adverse events Time: 0-28 days post vaccination
Measure: Occurrence of serious adverse reaction Time: 0-6 months post vaccination
Measure: Anti SARS-CoV-2 S IgG antibody response(ELISA) Time: 0, 14 days and 6 months post vaccination
Measure: Neutralizing antibody response to SARS-CoV-2 Time: 0 and 6 months post vaccination
Measure: Neutralizing antibody response to Ad5-vector Time: 0, 28 days and 6 months post vaccination
Measure: IFN-γ ELISpot responses to SARS-CoV-2 spike protein Time: 0 and 28 days post vaccination
No related HPO nodes (Using clinical trials)